P. Lange (Hvidovre, Denmark), A. Gulsvik (Bergen, Norway)
Does influenza vaccination increase consultations for corticosteroid prescriptions or exacerbations of asthma or chronic obstructive pulmonary disease?
L. J. Tata, T. Harrison, C. Smith, J. West, R. Hubbard (Nottingham, United Kingdom)
|   |
Antioxidant status and pulmonary function in patients with chronic airflow limitation
H. Ochs, B. Grant, J. Freudenheim, P. Muti, M. Trevisan, S. McCann, H. Schünemann (New York, United States Of America)
| |
Change in transfer factor for carbon monoxide. Predictors in a community cohort study
T. Duelien, P. S. Bakke, W. M. Vollmer, S. A. Buist, A. Gulsvik (Bergen, Norway; Portland, United States Of America)
| |
GOLD stage 0 and risk of COPD
I. Cerveri, S. Colato, M. C. Zoia, A. Corsico, M. Beccaria, P. Fulgoni, S. Villani, M. Ponzio, A. Marinoni, A. Foresi, E. Pozzi (Pavia, Italy)
| |
Physical activity and its determinants in a sample of severe COPD patients
J. Garcia-Aymerich, J. M. Antó (Barcelona, Spain)
| |
Measurement of COPD severity: development and validation of a survey-based instrument
M. D. Eisner, P. P. Katz, E. H. Yelin, L. Trupin, P. D. Blanc (San Francisco, United States Of America)
| |
Exacerbation types by COPD severity; risk of hospitalisation by patients not seeking treatment
G. C. Donaldson, T. A. Seemungal, T. M. Wilkinson, J. A. Wedzicha (London, United Kingdom)
| |
What happens to COPD patient during the last few years of their life?
F. L. Andersson, M. de Verdier, K. Svensson (Lund, Sweden)
| |